A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PEDIATRIC RITLECITINIB (PF-06651600) CAPSULES AND SPRAY CONGEALED BEADS RELATIVE TO ADULT CAPSULES IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Ritlecitinib (Primary) ; Ritlecitinib (Primary)
- Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
- 20 Jan 2022 Status changed from recruiting to completed.
- 05 Nov 2021 Planned End Date changed from 22 Nov 2021 to 20 Nov 2021.
- 05 Nov 2021 Planned primary completion date changed from 22 Nov 2021 to 20 Nov 2021.